# A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors

> **NCT02596503** · PHASE1 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 2 (actual)

## Conditions studied

- Relapsed Solid Tumors
- Refractory Solid Tumors

## Interventions

- **DRUG:** Eribulin
- **DRUG:** Irinotecan
- **OTHER:** Cefixime

## Key facts

- **NCT ID:** NCT02596503
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-21
- **Primary completion:** 2019-04
- **Final completion:** 2020-01-24
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2022-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02596503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02596503, "A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02596503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*